The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
Publications
[Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature].
La Revue de medecine interne 2004 Apr;25;310-4 — 2004 Apr — 310-4
Pleuropulmonary disease as a side-effect of treatment with bromocriptine.
Respiratory medicine 1998 Sep;92;1172-4 — 1998 Sep — 1172-4
Pleural effusion during bromocriptine exposure in two patients with pre-existing asbestos pleural plaques: a relationship?
The European respiratory journal 1997 Dec;10;2898-901 — 1997 Dec — 2898-901
Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos.
The European respiratory journal 1997 Dec;10;2711-5 — 1997 Dec — 2711-5
[Pleural effusion and severe edema of the lower limbs induced by bromocriptine].
La Revue de medecine interne 1996;17;680-3 — 1996 — 680-3
Suggestive evidence for bromocriptine-induced pleurisy.
The Netherlands journal of medicine 1996 Jun;48;232-6 — 1996 Jun — 232-6